In addition to direct inhibition of T cells via ROS, iNOS and mediators such as ARG1, TANs can also inhibit T cell anti-tumor immunity by recruiting TAMs and regulatory T cells (Tregs) to remodeling of the TME via CCL17 and CCL2 (53). Here, CCL2 is linked to neoplasm.